AU704059B2 - Use of no scavengers, inhibitors or antagonists in the treatment of migraine - Google Patents

Use of no scavengers, inhibitors or antagonists in the treatment of migraine Download PDF

Info

Publication number
AU704059B2
AU704059B2 AU24179/95A AU2417995A AU704059B2 AU 704059 B2 AU704059 B2 AU 704059B2 AU 24179/95 A AU24179/95 A AU 24179/95A AU 2417995 A AU2417995 A AU 2417995A AU 704059 B2 AU704059 B2 AU 704059B2
Authority
AU
Australia
Prior art keywords
inhibitor
antagonist
active principle
headache
scavenger
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU24179/95A
Other languages
English (en)
Other versions
AU2417995A (en
Inventor
Jes Olesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2417995A publication Critical patent/AU2417995A/en
Application granted granted Critical
Publication of AU704059B2 publication Critical patent/AU704059B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
AU24179/95A 1994-05-11 1995-05-10 Use of no scavengers, inhibitors or antagonists in the treatment of migraine Ceased AU704059B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94610027 1994-05-11
EP94610027 1994-05-11
PCT/IB1995/000415 WO1995031195A1 (en) 1994-05-11 1995-05-10 Use of no scavengers, inhibitors or antagonists in the treatment of migraine

Publications (2)

Publication Number Publication Date
AU2417995A AU2417995A (en) 1995-12-05
AU704059B2 true AU704059B2 (en) 1999-04-15

Family

ID=8218183

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24179/95A Ceased AU704059B2 (en) 1994-05-11 1995-05-10 Use of no scavengers, inhibitors or antagonists in the treatment of migraine

Country Status (12)

Country Link
US (1) US6265441B1 (enExample)
EP (1) EP0758890B1 (enExample)
JP (2) JPH10500129A (enExample)
AT (1) ATE291909T1 (enExample)
AU (1) AU704059B2 (enExample)
CA (1) CA2189762C (enExample)
DE (1) DE69534118T2 (enExample)
DK (1) DK0758890T3 (enExample)
ES (1) ES2238074T3 (enExample)
PT (1) PT758890E (enExample)
SI (1) SI0758890T1 (enExample)
WO (1) WO1995031195A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270531C (en) * 1996-11-05 2011-08-30 Head Explorer Aps A method for treating tension-type headache
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
AU1824300A (en) * 1998-11-23 2000-06-13 Linden Biotechnology, Inc. Combination products of a guanylate cyclase inhibitor and a local anesthetic forpain relief
US20060247216A1 (en) * 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
EP1578413A2 (en) * 2002-11-29 2005-09-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
US20080274206A1 (en) * 2004-10-07 2008-11-06 Ngen Pharmaceuticals N.V. Stabilised Oxygen Releasing Composition
WO2007009462A2 (en) * 2005-07-15 2007-01-25 Region Hovedstaden V/Glostrup Hospital Treatment of migraine and headaches
US20090191283A1 (en) * 2008-01-24 2009-07-30 Oronsky Bryan Todd Treatment of headaches, neck pain, joint pain and inflammatory-type pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263111A (en) * 1992-01-04 1993-07-14 Scras Arginine salt and amide inhibitors of no synthase and cyclooxygenase
AU7387594A (en) * 1993-08-12 1995-03-14 Astra Aktiebolag Amidine derivatives with nitric oxide synthetase activities
AU7390794A (en) * 1993-08-25 1995-03-21 Anormed Inc. Pharmaceutical compositions comprising metal complexes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707494B1 (fr) 1993-07-02 1995-08-25 Roussel Uclaf Nouvelle utilisation de dérivés de la béta-naphtoquinone ainsi que de leurs sels.
EP0759027B1 (en) * 1994-05-07 1999-08-04 Astra Aktiebolag Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263111A (en) * 1992-01-04 1993-07-14 Scras Arginine salt and amide inhibitors of no synthase and cyclooxygenase
AU7387594A (en) * 1993-08-12 1995-03-14 Astra Aktiebolag Amidine derivatives with nitric oxide synthetase activities
AU7390794A (en) * 1993-08-25 1995-03-21 Anormed Inc. Pharmaceutical compositions comprising metal complexes

Also Published As

Publication number Publication date
EP0758890A1 (en) 1997-02-26
DK0758890T3 (da) 2005-04-18
US6265441B1 (en) 2001-07-24
SI0758890T1 (enExample) 2005-08-31
JPH10500129A (ja) 1998-01-06
CA2189762A1 (en) 1995-11-23
CA2189762C (en) 2009-01-13
JP2007137906A (ja) 2007-06-07
AU2417995A (en) 1995-12-05
ES2238074T3 (es) 2005-08-16
DE69534118T2 (de) 2006-02-09
EP0758890B1 (en) 2005-03-30
DE69534118D1 (de) 2005-05-04
PT758890E (pt) 2005-06-30
ATE291909T1 (de) 2005-04-15
WO1995031195A1 (en) 1995-11-23

Similar Documents

Publication Publication Date Title
Olesen et al. The nitric oxide hypothesis of migraine and other vascular headaches
Iadecola et al. Nitric oxide synthase inhibition and cerebrovascular regulation
US20080009467A1 (en) Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
RU2039556C1 (ru) Фармацевтическая композиция противоалкогольного, стимулирующего энергетический обмен, кислотообразующую и секреторную функцию слизистой желудка, радиопротекторного и противохолерного действия, способ профилактики и лечения алкогольного опьянения и алкогольного абстинентного синдрома, способ стимуляции энергетического обмена, способ стимуляции и диагностики кислотообразующей и секреторной функции слизистой желудка и способ защиты от радиационного поражения теплокровных животных
JPS58154511A (ja) 体重減少剤
JPH027572B2 (enExample)
AU704059B2 (en) Use of no scavengers, inhibitors or antagonists in the treatment of migraine
Rinne et al. Plasma concentration of levodopa in patients with Parkinson’s disease: response to administration of levodopa alone or combined with a decarboxylase inhibitor and clinical correlations
JPH03501126A (ja) アルコールへの病理学的渇望の発達を抑制する組成物
WO2009005519A1 (en) Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US5041429A (en) Cell activators, circulatory ameliorators and edible compositions
US4540582A (en) Treatment of seizure disorders and pharmaceutical compositions useful therein
WO2003013514A1 (en) Improving neurological functions
JPS63501498A (ja) Ｌ‐ドーパの新規誘導体、その製法とそれを含有する医薬組成物
Thomsen et al. The role of nitric oxide in migraine pain: therapeutic implications
US5846977A (en) Nerve growth factor production accelerators and compositions for preventing or treating neuronal degeneration
US4595697A (en) Treatment of seizure disorders and pharmaceutical compositions useful therein
JPH07508258A (ja) モノシアロガングリオシドｇｍ↓１またはその誘導体を含有する，パーキンソン病の治療に適する医薬組成物
BG63863B1 (bg) Използване на производни на сулфаминовата киселина, ацил сулфонамиди или сулфамоил карбамати за получаването на средство за понижаване на липопротеиновите нива
CA2459719C (en) Pharmaceutical composition comprising gamma-butyrobetaine
EP0108017B1 (fr) Association renfermant à titre de principes actifs, un analgésique central et la vitamine B12 ou un de ses analogues
US3865942A (en) Method of increasing cerebral blood flow
Drieu et al. In vivo studies of the pharmacological and biochemical activities of Ginkgo biloba extract (EGb 761) and its constituents
Blackwell et al. Antidepressant drugs
HU229421B1 (en) Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q10